Expertise in
12
conditions

Dr. Atul Kumar

Oncology
2237 Trinity Dr Ste B, 
Los Alamos, NM 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
2237 Trinity Dr Ste B, 
Los Alamos, NM 

Overview

Atul Kumar is an Oncologist practicing medicine in Los Alamos, New Mexico.

Dr. Kumar is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, Thrombectomy, and Vitrectomy.

Dr. Kumar is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 99 peer reviewed articles and participating in 18 clinical trials. Dr. Kumar is currently accepting new patients.

Graduate Institution

Temple University School Of Medicine

Residency

Montefiore Medical Center

Specialties

Oncology

Licenses

Internal Medicine in CA

Board Certifications

American Board Of Internal Medicine

Fellowships

Stanford University School of Medicine

Hospital Affiliations

Unm Hospital
Yuma Regional Medical Center
Lincoln County Medical Center
Regional West Medical Center
Christus St Vincent Regional Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Christus St Vincent Medical Oncology
2237 Trinity Dr Ste B, Los Alamos, NM 87544
Other Locations
Christus St. Vincent Medical Oncologists
445 Saint Michaels Dr, Santa Fe, NM 87505

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Talazoparib
Study Phase: Phase 2
View 8 Less Clinical Trials

99 Total Publications

White Matter Hyperintensities on Admission CT Are Associated with Worse Outcomes but not Cerebral Edema or Hemorrhagic Transformation after Large Vessel Occlusion Stroke.
White Matter Hyperintensities on Admission CT Are Associated with Worse Outcomes but not Cerebral Edema or Hemorrhagic Transformation after Large Vessel Occlusion Stroke.
Journal: Research square
Published: June 04, 2026
Similar Doctors
Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Northern New Mexico Cancer Care

3917 West Rd Ste 225, 
Los Alamos, NM 
 (177.9 miles away)
505-662-3450
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Karen Russo is an Oncologist practicing medicine in Los Alamos, New Mexico. Dr. Russo is highly rated in 37 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Breast Cancer. Dr. Russo is board certified in American Board Of Internal Medicine. Dr. Russo is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral required

Christus St Vincent Medical Oncologists

490 W Zia Rd Ste 210, 
Santa Fe, NM 
 (159.1 miles away)
505-913-8900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ursa Brown is an Oncologist practicing medicine in Santa Fe, New Mexico. Dr. Brown is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Brown is board certified in American Board Of Internal Medicine. Dr. Brown is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Office

2025 Galisteo St Ste B, 
Santa Fe, NM 
 (159.1 miles away)
505-843-7813
Languages Spoken:
English
See accepted insurances

Karen Finkelstein is an Oncologist practicing medicine in Santa Fe, New Mexico. Dr. Finkelstein is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hernia Surgery.

Frequently Asked Questions about Dr. Atul Kumar

How do I make an appointment with Dr. Atul Kumar?

You can book an appointment with Dr. Atul Kumar by calling their office at 505-662-8870. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Atul Kumar a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Atul Kumar is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Atul Kumar specialize in?

While Dr. Atul Kumar is a Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Atul Kumar participate in research or clinical trials?

Yes. Dr. Atul Kumar has published 99 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Atul Kumar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Atul Kumar accept my insurance?

Dr. Atul Kumar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 505-662-8870 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile